NOVC.DE
Novo Nordisk A/S [NOVC.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NOVC.DE Stock Summary
In the News
NOVC.DE Financial details
Company Rating
Strong Buy
Market Cap
406.69B
Income
75.31B
Revenue
214.49B
Book val./share
20.72
Cash/share
10.6
Dividend
11.15
Dividend %
1.63%
Employees
59.34K
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
22.78
Forward P/E
-
PEG
6.15
P/S
15.08
P/B
16.93
P/C
8.62
P/FCF
44.98
Quick Ratio
0.68
Current Ratio
0.88
Debt / Equity
0.29
LT Debt / Equity
0.21
-
-
EPS (TTM)
28.49
EPS next Y
-
EPS next Q
-
EPS this Y
17.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9%
Revenue last 5Y
9.61%
Revenue Q/Q
8.16%
EPS Q/Q
-41.97%
-
-
-
-
SMA20
-1.06%
SMA50
-
SMA100
-
Inst Own
0.02%
Inst Trans
1.73%
ROA
24%
ROE
81%
ROC
0.62%
Gross Margin
84%
Oper. Margin
38%
Profit Margin
33%
Payout
42%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
51.65-185.12
52W High
-50.59%
52W Low
+79.22%
RSI
46
Rel Volume
0.53
Avg Volume
51.04K
Volume
26.81K
Perf Week
-3.33%
Perf Month
-
Perf Quarter
-
Perf Half Y
-3.99%
-
-
-
-
Beta
0.242117
-
-
Volatility
1.53%, 1.92%
Prev Close
0%
Price
91.4
Change
-1.98%
NOVC.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 46.13 | 51.3 | 54.25 | 61.13 | 77.87 | |
| Net income per share | 15.93 | 16.38 | 18.01 | 20.74 | 24.44 | |
| Operating cash flow per share | 18.4 | 19.67 | 22.2 | 23.88 | 34.72 | |
| Free cash flow per share | 13.28 | 14.95 | 12.76 | 20.67 | 28.22 | |
| Cash per share | 6.45 | 6.51 | 5.45 | 7.59 | 10.37 | |
| Book value per share | 21.38 | 24.21 | 27.06 | 30.72 | 36.74 | |
| Tangible book value per share | 19.26 | 21.76 | 18.23 | 11.97 | 14.11 | |
| Share holders equity per share | 21.38 | 24.21 | 27.06 | 30.72 | 36.74 | |
| Interest debt per share | 0.25 | 1.98 | 4.59 | 12.63 | 11.51 | |
| Market cap | 370B | 464.29B | 504.56B | 845.4B | 1073.08B | |
| Enterprise value | 354.87B | 453.3B | 502.16B | 861.33B | 1086.21B | |
| P/E ratio | 9.58 | 11.92 | 11.97 | 17.7 | 19.33 | |
| Price to sales ratio | 3.31 | 3.81 | 3.97 | 6 | 6.06 | |
| POCF ratio | 8.29 | 9.92 | 9.71 | 15.37 | 13.6 | |
| PFCF ratio | 11.49 | 13.06 | 16.89 | 17.76 | 16.73 | |
| P/B Ratio | 7.14 | 8.06 | 7.97 | 11.95 | 12.85 | |
| PTB ratio | 7.14 | 8.06 | 7.97 | 11.95 | 12.85 | |
| EV to sales | 3.17 | 3.71 | 3.96 | 6.12 | 6.14 | |
| Enterprise value over EBITDA | 6.94 | 7.84 | 8.34 | 12.75 | 13.24 | |
| EV to operating cash flow | 7.95 | 9.69 | 9.67 | 15.66 | 13.77 | |
| EV to free cash flow | 11.02 | 12.75 | 16.81 | 18.09 | 16.94 | |
| Earnings yield | 0.1 | 0.08 | 0.08 | 0.06 | 0.05 | |
| Free cash flow yield | 0.09 | 0.08 | 0.06 | 0.06 | 0.06 | |
| Debt to equity | 0.01 | 0.08 | 0.16 | 0.38 | 0.31 | |
| Debt to assets | 0 | 0.04 | 0.07 | 0.14 | 0.11 | |
| Net debt to EBITDA | -0.3 | -0.19 | -0.04 | 0.24 | 0.16 | |
| Current ratio | 1.09 | 1.06 | 0.94 | 0.86 | 0.89 | |
| Interest coverage | 555.86 | 238.56 | 138.78 | 23.93 | 197.91 | |
| Income quality | 1.16 | 1.2 | 1.23 | 1.15 | 1.42 | |
| Dividend Yield | 0.05 | 0.04 | 0.04 | 0.03 | 0.02 | |
| Payout ratio | 0.49 | 0.5 | 0.48 | 0.45 | 0.46 | |
| Sales general and administrative to revenue | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.13 | 0.12 | 0.12 | 0.13 | 0.14 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.14 | 0.22 | 0.21 | |
| Capex to operating cash flow | -0.28 | -0.24 | -0.43 | -0.13 | -0.19 | |
| Capex to revenue | -0.11 | -0.09 | -0.17 | -0.05 | -0.08 | |
| Capex to depreciation | -3.16 | -1.98 | -3.84 | -1.23 | -2 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Graham number | 87.55 | 94.45 | 104.71 | 119.71 | 142.13 | |
| ROIC | 0.73 | 0.64 | 0.55 | 0.47 | 0.53 | |
| Return on tangible assets | 0.37 | 0.33 | 0.34 | 0.32 | 0.29 | |
| Graham Net | -6.17 | -9.19 | -15.14 | -26.65 | -34.71 | |
| Working capital | 4.9B | 3.47B | -4.46B | -13.92B | -12.75B | |
| Tangible asset value | 46.69B | 51.76B | 42.67B | 27.58B | 32.07B | |
| Net current asset value | 137M | -5.56B | -15.79B | -38.17B | -49.58B | |
| Invested capital | 0.01 | 0.08 | 0.16 | 0.38 | 0.31 | |
| Average receivables | 25.22B | 28.02B | 30.67B | 39.49B | 52.15B | |
| Average payables | 6.18B | 6.56B | 6.04B | 7.29B | 12.23B | |
| Average inventory | 15.85B | 16.99B | 18.09B | 19.08B | 22B | |
| Days sales outstanding | 87.76 | 87.2 | 92.54 | 121.32 | 118.61 | |
| Days payables outstanding | 139.98 | 115.53 | 99.69 | 136.85 | 199.99 | |
| Days of inventory on hand | 338.46 | 320.54 | 323.22 | 302.72 | 312.91 | |
| Receivables turnover | 4.16 | 4.19 | 3.94 | 3.01 | 3.08 | |
| Payables turnover | 2.61 | 3.16 | 3.66 | 2.67 | 1.83 | |
| Inventory turnover | 1.08 | 1.14 | 1.13 | 1.21 | 1.17 | |
| ROE | 0.75 | 0.68 | 0.67 | 0.68 | 0.67 | |
| Capex per share | -5.12 | -4.72 | -9.44 | -3.21 | -6.49 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 20.09 | 21.2 | 23.65 | 24.12 | 13.08 | |
| Net income per share | 6.35 | 5.99 | 8.78 | 8.63 | 5.01 | |
| Operating cash flow per share | 10.69 | 3.13 | 13.21 | 12.69 | 9.13 | |
| Free cash flow per share | 8.82 | 0.41 | 11.08 | 9.57 | 6.76 | |
| Cash per share | 16.52 | 10.39 | 12.31 | 16.17 | 10.6 | |
| Book value per share | 33.8 | 36.8 | 35.4 | 40.19 | 20.72 | |
| Tangible book value per share | 33.8 | 14.14 | 35.4 | 40.19 | 20.72 | |
| Share holders equity per share | 33.8 | 36.8 | 35.4 | 40.19 | 20.72 | |
| Interest debt per share | 13.09 | 7.82 | 11.81 | 11.54 | 6.39 | |
| Market cap | 862.99B | 1071.29B | 1226.8B | 1233.26B | 2889.73B | |
| Enterprise value | 860.49B | 1084.42B | 1237.39B | 1237.39B | 2886.12B | |
| P/E ratio | 14.98 | 19.7 | 15.48 | 15.87 | 32.14 | |
| Price to sales ratio | 18.94 | 22.28 | 22.99 | 22.71 | 49.2 | |
| POCF ratio | 35.6 | 150.86 | 41.15 | 43.16 | 70.54 | |
| PFCF ratio | 43.12 | 1.15K | 49.05 | 57.25 | 95.24 | |
| P/B Ratio | 11.25 | 12.83 | 15.36 | 13.63 | 31.08 | |
| PTB ratio | 11.25 | 12.83 | 15.36 | 13.63 | 31.08 | |
| EV to sales | 18.88 | 22.55 | 23.19 | 22.79 | 49.14 | |
| Enterprise value over EBITDA | 36.16 | 105.14 | 44.87 | 46.32 | 88.11 | |
| EV to operating cash flow | 35.5 | 152.71 | 41.5 | 43.3 | 70.45 | |
| EV to free cash flow | 42.99 | 1.17K | 49.47 | 57.44 | 95.12 | |
| Earnings yield | 0.02 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Free cash flow yield | 0.02 | 0 | 0.02 | 0.02 | 0.01 | |
| Debt to equity | 0.34 | 0.31 | 0.32 | 0.28 | 0.29 | |
| Debt to assets | 0.11 | 0.11 | 0.1 | 0.09 | 0.09 | |
| Net debt to EBITDA | -0.1 | 1.27 | 0.38 | 0.15 | -0.11 | |
| Current ratio | 0.92 | 0.89 | 0.86 | 0.88 | 0.82 | |
| Interest coverage | 5.42 | -1.03 | 22.29 | 85.01 | 12.41 | |
| Income quality | 1.68 | 0.52 | 1.5 | 1.47 | 1.82 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | 0.67 | 0 | 0.93 | 0 | 0.6 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.12 | 0.17 | 0.13 | 0.13 | 0.14 | |
| Intangibles to total assets | 0.19 | 0.21 | 0.2 | 0.18 | 0.19 | |
| Capex to operating cash flow | -0.17 | -0.87 | -0.16 | -0.25 | -0.26 | |
| Capex to revenue | -0.09 | -0.13 | -0.09 | -0.13 | -0.18 | |
| Capex to depreciation | -2.07 | -3.03 | -2.79 | -3.23 | -4.21 | |
| Stock based compensation to revenue | 0 | 0 | 0 | -0.08 | -0.06 | |
| Graham number | 69.49 | 70.44 | 83.62 | 88.33 | 48.31 | |
| ROIC | 0.16 | 0.06 | 0.19 | 0.16 | 0.18 | |
| Return on tangible assets | 0.07 | 0.07 | 0.1 | 0.08 | 0.09 | |
| Graham Net | -33.92 | -34.77 | -38.17 | -38.63 | -21.89 | |
| Working capital | -10.78B | -12.75B | -18.02B | -19.07B | -30.35B | |
| Tangible asset value | 29.76B | 32.07B | 29.39B | 39.72B | 37.27B | |
| Net current asset value | -46.67B | -49.58B | -56.21B | -52.73B | -64.91B | |
| Invested capital | 0.34 | 0.31 | 0.32 | 0.28 | 0.29 | |
| Average receivables | 50.07B | 55.51B | 57.71B | 64.22B | 66.24B | |
| Average payables | 11.48B | 11.95B | 12.82B | 13.92B | 18.95B | |
| Average inventory | 22.46B | 23.81B | 25B | 26.82B | 28.78B | |
| Days sales outstanding | 105.69 | 107.62 | 97.68 | 116.89 | 94.95 | |
| Days payables outstanding | 103.88 | 169.79 | 110.55 | 203.78 | 186.3 | |
| Days of inventory on hand | 290.28 | 265.66 | 281.76 | 321 | 273.66 | |
| Receivables turnover | 0.85 | 0.84 | 0.92 | 0.77 | 0.95 | |
| Payables turnover | 0.87 | 0.53 | 0.81 | 0.44 | 0.48 | |
| Inventory turnover | 0.31 | 0.34 | 0.32 | 0.28 | 0.33 | |
| ROE | 0.19 | 0.16 | 0.25 | 0.21 | 0.24 | |
| Capex per share | -1.86 | -2.72 | -2.13 | -3.12 | -2.37 |
NOVC.DE Frequently Asked Questions
What is Novo Nordisk A/S stock symbol ?
Novo Nordisk A/S is a DK stock and trading under the symbol NOVC.DE
What is Novo Nordisk A/S stock quote today ?
Novo Nordisk A/S stock price is $91.4 today.
Is Novo Nordisk A/S stock public?
Yes, Novo Nordisk A/S is a publicly traded company.
Company Profile
- Volume Average 51.04K
- Market Capitalization 406.69B
- Employee 59.34K
- CEO Mr. Lars Fruergaard Jorgensen
- Headquarters Bagsvaerd,DK
- IPO Date 2001-06-07
-
Website
https://www.novonordisk.com/ 
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
